Adjunctive rosiglitazone treatment for severe pediatric malaria: A randomized placebo-controlled trial in Mozambican children

In 2021 malaria caused ∼247 million clinical episodes, 2-4 million cases of severe disease and an estimated 619,000 deaths [1]. The highest mortality rates occur in sub-Saharan African children under the age of 5. The majority of the severe sequelae and deaths are due to Plasmodium falciparum. The treatment of choice fo r severe malaria (SM) in both children and adults is parenteral artesunate. However, despite this potent antimalarial, mortality rates remain high (8.5% in children and 15% in adults for SM; 18% and 30% respectively for cerebral malaria [CM]) [2,3].

Source: International Journal of Infectious Diseases - November 25, 2023 Category: Infectious Diseases Authors: Rosauro Varo, Valerie M. Crowley, Humberto Mucasse, Antonio Sitoe, Justina Bramugy, Lena Serghides, Andrea M. Weckman, Clara Erice, Rubao Bila, Pio Vitorino, Campos Mucasse, Marta Valente, Sara Ajanovic, N úria Balanza, Kathleen Zhong, Yiovanna Derpsch, Source Type: research